New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY From The Last 14 Days
Check below for free stories on MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 11, 2014
07:06 EDTSNYVIVUS announces avanafil clinical data presentation
Subscribe for More Information
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
11:42 EDTGSKReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
10:05 EDTCELGCelgene CEO Hugin says 'excited' about guidance for the year
Subscribe for More Information
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:34 EDTABTAbbott completes enrollment of Absorb clinical trials in U.S., Japan and China
Subscribe for More Information
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
07:04 EDTBMYBristol-Myers presents Phase III data on all-oral Daclatasvir and Asunaprevir
Subscribe for More Information
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
April 9, 2014
12:12 EDTCELGMarkman documents appear to favor Celgene, The Street says
Public documents for the pre-trial Markman hearing appear to favor Celgene over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents, The Street's Adam Feuerstein reports. Shares of Celgene are up 5% to $145.33 in mid-day trading. Reference Link
11:43 EDTABT, BMY, MRKGilead defended by analysts after recent pullback
Subscribe for More Information
07:23 EDTJNJ, BMY, MRKEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTMRK, SNY, NVSReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
07:09 EDTJNJJohnson & Johnson outlook positive into Q1 results, says Bernstein
Bernstein expects Johnson & Johnson's Q1 EPS to come in slightly above the consensus estimate, with strength in pharmaceuticals more than offsetting lackluster Medical Devices & Diagnostics growth, according to the firm. Bernstein keeps an Outperform rating on the stock.
April 8, 2014
11:03 EDTBMY, GSK, SNY, PFE, MRKPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use